Latest Breaking News On - Ken blount - Page 4 : vimarsana.com

Ferring, Rebiotix & MyBiotics in vaginal health R&D pact

Ferring Pharmaceuticals, Rebiotix and MyBiotics Pharma are to enter a research collaboration that focuses on live microbiota-based biotherapeutics to address bacterial vaginosis (BV). The agreement looks to expand on each firms’ expertise in reproductive medicine and women’s health, by creating standardised, stable live microbiota-based formulations addressing the vaginal infection. Common among women of reproductive age, the condition is linked to an increased risk of miscarriage, as well as problems during pregnancy and fertility issues. “Today’s agreement is an important evolution of our long-standing relationship with Ferring in the field of microbiota-based therapies for the benefit of women s health, including reproduction and pregnancy,” says MyBiotics’ CEO, David Daboush.

David daboushKen blountMicrobiome researchFerring pharmaceuticalsChief scientific officerVice presidentWomen 039s healthProbiotics amp prebioticsகேன் புளூட்ஃபெர்ரிங் மருந்துகள்தலைமை அறிவியல் அதிகாரிதுணை ப்ரெஸிடெஂட்

Ferring, Israel s MyBiotics look to microbiome to treat vaginal infection

Ferring, Israel s MyBiotics look to microbiome to treat vaginal infection
timesofisrael.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timesofisrael.com Daily Mail and Mail on Sunday newspapers.

David daboushKen blountFerring rebiotix incFerring pharmaceuticalsMybiotics pharma ltdMybiotics pharmaRebiotix incகேன் புளூட்ஃபெர்ரிங் மருந்துகள்

Redirecting to Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health Ferring Pharmaceuticals, Rebiotix Inc., a Ferring Company, and MyBiotics Pharma Ltd. today announced a multi-year strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial vaginosis, a common vaginal infection among women of reproductive age linked to increased risk of miscarriage and complications for pregnancy and fertility.1,2,3 The collaboration is an important step forward in harnessing the power of the human microbiome in this area of women’s health. Currently bacterial vaginosis is treated with antibiotics, which can disrupt the vaginal microbiome, and it’s common for bacterial vaginosis to return following treatment.4 The aim of a microbiota-based treatment would be to reduce the need for antibiotic use and provide a long-term treatment solution.

David daboushKen blountMybiotic mycrobeMicrobiome researchUs national library of medicineFerring pharmaceuticalsMybiotics pharma ltdFerring companyRebiotix incMybiotics pharmaChief scientific officerVice presidentGlobal burdenBacterial vaginosisSystematic reviewReproduction update

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Lindsey rodgerDavid daboushKen blountMybiotic mycrobeMicrobiome researchUs national library of medicineFerring pharmaceuticalsMybiotics pharma ltdFerring companyCorporate communicationsRebiotix incMybiotics pharmaChief scientific officerVice presidentGlobal burdenBacterial vaginosis